Related Experiment Videos
Platelet factor 4 as a marker of platelet activation in patients with acute myocardial infarction
V Dymicka-Piekarska1, H Kemona, M Mantur
1Department of Clinical Laboratory Diagnostics, Medical Academy of Białystok.
Insights
Platelet factor 4 (PF 4) levels change during myocardial infarction (MI). Thrombolytic therapy, including streptokinase, heparin, and aspirin, effectively inhibits platelet activation in MI patients.
Area of Science:
- Cardiology
- Hematology
- Biochemistry
Background:
- Platelets play a crucial role in the pathogenesis of ischemic heart disease and myocardial infarction (MI).
- Platelet activation leads to the release of alpha granule proteins, such as platelet factor 4 (PF 4).
- PF 4 serves as a marker for platelet activation.
Purpose of the Study:
- To evaluate the dynamics of PF 4 in patients with acute myocardial infarction (MI).
- To assess the influence of disease duration and treatment type on PF 4 levels.
- To investigate the effect of thrombolytic therapy on platelet activation markers.
Main Methods:
- Investigated 29 patients with acute MI, divided into two treatment groups (heparin/aspirin vs. streptokinase/heparin/aspirin).
- Included a control group of 21 healthy subjects.
- Measured PF 4 concentration on days 1, 3, 5, 8, and 11 post-MI using an immunoenzymatic method.
Main Results:
- Observed changes in PF 4 levels during the course of myocardial infarction.
- Demonstrated that thrombolytic therapy significantly inhibits platelet activation, as indicated by PF 4 levels.
- Treatment with streptokinase, heparin, and aspirin showed a greater inhibition of platelet activation compared to heparin and aspirin alone.
Conclusions:
- Platelet factor 4 dynamics reflect platelet activation status in acute myocardial infarction.
- Thrombolytic therapy is effective in reducing platelet activation during MI.
- The findings support the importance of antiplatelet and thrombolytic strategies in managing acute myocardial infarction.
Abstract:
The aim of the present study was evaluate dynamics of platelet factor 4, as a marker of platelet activation, in patients with acute myocardial infarction according to the disease duration and type of treatment. In the recent years much attention has been paid to the role of platelets in the pathogenesis of ischaemic disease and myocardial infarction. Rupture or splitting of atheroma and increased platelet activation are a direct cause of acute thrombotic process in coronary vessels. During platelet activation alpha granules release proteins, e.g. platelet factor 4 (PF 4). We investigated 29 patients with acute myocardial infarction (MI); the patients were divided into two groups: group A--15 patients treated with heparin and aspirin; group B--14 patients treated with streptokinase, heparin and aspirin. Control group (C) consisted of 21 healthy subjects. PF 4 concentration was determined on the 1st, 3rd, 5th, 8th, 11th day of MI using the immunoenzymatic method. Our results indicate that in the course of myocardial infarction there is a change in the platelet factor 4 and that thrombolytic therapy inhibits platelet activation.